SecBot SecBot
SECBOTREPLAY Home › Report › CELC

CELC · sNDA accepted, PDUFA June 2027

Celcuity Inc. · PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET

At the news

BULLISHIMPACT 5/10

PRESS-RELEASE filed Nov 9, 2026 at 08:30 ET

Celcuity announced FDA acceptance of its sNDA for REVTORPYK (gedatolisib) in HR+/HER2- advanced breast cancer with PIK3CA mutations, with a PDUFA date of June 25, 2027. This expands the potential label to all HR+/HER2- advanced breast cancer patients regardless of PIK3CA status, building on the July 2026 approval for PIK3CA wild-type tumors.

  • FDA accepted sNDA for REVTORPYK in HR+/HER2- advanced breast cancer with PIK3CA mutation
  • PDUFA goal date set for June 25, 2027
  • Submission based on PIK3CA mutant cohort of Phase 3 VIKTORIA-1 trial
  • REVTORPYK already approved (July 14, 2026) for PIK3CA wild-type advanced breast cancer

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access